TenderlineUK
Procurement Intelligence
Official OCDS
Find a Tender
complete
Official procurement procedure

NHS Branded Medicines Tranche A - NOFE and Midlands & East and Natalizumab for London & SOFE - 1 September 2026

No classification published
Location not published
Official notice
Published value
£877,670,570
Submission deadline 17 Apr 2026, 13:00 BST
Lots published2
Procurement Executive Summary
AI & Search Synopsis
Generated from official OCDS record
Tenderline Synopsis: NHS England: "NHS Branded Medicines Tranche A - NOFE and Midlands & East and Natalizumab for London & SOFE - 1 September 2026". Published status: complete. Published value: £877,670,570. 2 published lots. Recorded submission deadline: 17 Apr 2026, 13:00 BST. See the official notice for participation instructions.
Contracting AuthorityNHS EnglandScope & CategoriesNot publishedSubmission Window
Closed
17 Apr 2026, 13:00 BST
Submission GatewayDirect notice routeLegal Basis & RegimeStandard procurementEstimated Value (exc. VAT)£877,670,570
Bidder Intelligence · Authority Profile: NHS England
Market Analytics
View Authority Profile →
Derived from OCDS awards & bid statistics
Published history for NHS England. These figures describe retained records, not a forecast of bids or a measure of buyer bias.
Average Price Reduction
Not availableInsufficient comparable data
Requires at least 5 comparable procedures
Competition Density
22.8Bids / Report
7.7% of reports have one bid
Supplier ConcentrationModerate Concentration
Anna FreudTop vendor: 29.6% of attributable value
Payment Terms
Check noticePublished terms
Payment obligations depend on the applicable regime and contract. Consult the official documents.
Coverage: 859 active published awards; 13 bid reports (which may be per lot). Supplier values exclude multi-supplier awards, frameworks and DPS, and use GBP only. They are published award values, not payments. Price reduction compares single-lot, single-award, single-supplier GBP procedures with explicitly non-framework/non-DPS status; increases remain in the average. Unpublished data stays unknown. Awarded suppliers are winners, not all bidders.
Historical Awarded Suppliers With This Authority:
Supplier NameHistoric AwardsAttributable GBP Value
Anna Freud1 win£5,862,540
Anglia Ruskin University1 win£4,809,159
NHS Shared Business Services Limited1 win£4,393,727
Pearson Professional Assessments Limited1 win£4,374,320
Timewise Foundation CIC1 win£166,667
Procedure terms
Contracting AuthorityNHS England
Procedure methodNot published
Procurement categoryNot published
Statuscomplete
Framework / DPSFramework
CompetitionNot published
Above thresholdNot published
Legal basisNot published
Tender period startsNot published
Clarification deadlineNot published
Electronic submissionNot published
Submission languagesNot published
Published21 Jul 2026, 11:16 BST
Last source update21 Jul 2026, 11:16 BST
Recurring procurementNot published
ClassificationNot published
Delivery areaLocation not published
OCIDocds-h6vhtk-051c98
What is being bought
NHS Branded Framework Agreement – Lot 1 - Tranche A for the North of England and Midlands & East. Period of Framework Agreement: 1st September 2026 to 31st August 2028 with an option or option(s) to extend (at the authority’s discretion for a further 24 months. Lot 2 - Natalizumab for London and South of England. The period of Framework Agreement: 1st September 2026 to 31st August 2027 with an option or option(s) to extend for a further 12 months.
What changed
From the official release history
  1. Official notice release published
    21 Jul 2026, 11:16 BST
  2. Official notice release published
    9 Jul 2026, 15:45 BST
  3. tender value changed
    23 Jun 2026, 12:33 BST
  4. Status changed to complete
    23 Jun 2026, 12:33 BST
  5. Official notice release published
    23 Jun 2026, 12:33 BST
  6. Submission deadline changed to published date
    23 Jun 2026, 12:33 BST
  7. Published value updated to £877,670,570
    17 Mar 2026, 12:14 GMT
  8. Status changed to active
    17 Mar 2026, 12:14 GMT
  9. Official notice release published
    17 Mar 2026, 12:14 GMT
  10. Submission deadline changed to 17 Apr 2026, 13:00 BST
    17 Mar 2026, 12:14 GMT
  11. Official notice release published
    13 Mar 2026, 15:08 GMT
  12. Published value updated to £456,000,000
    13 Jan 2026, 09:57 GMT
  13. Official notice release published
    13 Jan 2026, 09:57 GMT
  14. Official notice release published
    3 Jun 2025, 12:41 BST
  15. Published value updated to £206,835,684
    22 May 2025, 09:34 BST
  16. Status changed to planned
    22 May 2025, 09:34 BST
  17. Official notice release published
    22 May 2025, 09:34 BST
  18. Buyer information updated
    22 May 2025, 09:34 BST
Lots and requirements (2)
Published by the contracting authority
  • Lot 1 · #1
    Individual lot title not published
    complete
    Published valueNot published
    The source published no individual title or description for this lot.
    Contract periodNot published
    EligibilityNot published
    Options / renewalNot published
  • Lot 2 · #2
    Individual lot title not published
    complete
    Published valueNot published
    The source published no individual title or description for this lot.
    Contract periodNot published
    EligibilityNot published
    Options / renewalNot published
Timeline
  1. Procedure published
    21 Jul 2026, 11:16 BST
  2. Submission deadline
    17 Apr 2026, 13:00 BST
  3. Award active
    Not published · Not published
  4. Award active
    Not published · Not published
  5. Contract active
    Signed 6 Jul 2026, 00:00 BST · £665,389,588
  6. Contract active
    Signed 6 Jul 2026, 00:00 BST · £35,312,548
Commercial outcome and competition
Awards
AVENTIS PHARMA LIMITED t-a Sanofi, Accord UK Ltd, Amgen Ltd, BAYER PLC, BIOGEN IDEC LIMITED, C. S. T. PHARMA LIMITED, CHUGAI PHARMA LIMITED, ELI LILLY & COMPANY LTD, GEDEON RICHTER (UK) LIMITED, GLAXOSMITHKLINE UK LIMITED, LABORATORIES JUVISE PHARMACEUTICALS, MERCK SERONO LIMITED, MILPHARM LIMITED, NAPP PHARMACEUTICALS LTD, NOVO NORDISK, Orifarm UK Ltd, PFIZER LIMITED, PHARMACOSMOS UK LTD, ROCHE PRODUCTS LIMITED, SANDOZ LIMITED, TEVA UK LIMITED, THORNTON & ROSS LIMITED, VIATRIS UK HEALTHCARE LIMITED, VIFOR PHARMA UK LTD
Not published · Not published · active
BIOGEN IDEC LIMITED, SANDOZ LIMITED
Not published · Not published · active
Contracts
Lot 1 - CM/PHR/25/5730/01 - NHS National Branded Tranche B - NOFE & MAE
£665,389,588 · signed 6 Jul 2026, 00:00 BST · active
Contract period: 1 Sept 2026, 00:00 BST — 31 Aug 2028, 23:59 BST
Lot 2 - CM/PHR/25/5730/02 - Natalizumab for London and South of England
£35,312,548 · signed 6 Jul 2026, 00:00 BST · active
Contract period: 1 Sept 2026, 00:00 BST — 31 Aug 2027, 23:59 BST
Bid statisticsNo aggregate bid statistics published
Buyer and organisations in this procedure

NHS England

Contracting authority GB-PPON-PDPT-3135-BWWY
View buyer profile
Documents (1)
Official links; attachments are not copied

  • Not published

    tender
    conflictOfInterest
Related procedures (0)
No data
No related procedures published